Matinas BioPharma
MTNB
42 hedge funds and large institutions have $6.91M invested in Matinas BioPharma in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.
23% more capital invested
Capital invested by funds: $5.61M → $6.91M (+$1.3M)
0% less ownership
Funds ownership: 0.24% → 0.23% (-0%)
18% less funds holding
Funds holding: 51 → 42 (-9)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$133K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$30.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$16.2K |
| 4 |
SW
Simplicity Wealth
Summit,
New Jersey
|
+$14.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$68.7K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$49.3K |
| 3 |
VF
Virtu Financial
New York
|
-$35K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$29.7K |
| 5 |
Bank of New York Mellon
New York
|
-$16.6K |
MTNB Hedge Fund Activity: Q1 2024 in Review
42 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2024, worth a combined $6.91M — up 23% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MTNB and 3 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $133K. The largest seller was Connective Capital Management, exiting entirely with an estimated $68.7K sold.
- 42 institutional investors held Matinas BioPharma (MTNB) as of Q1 2024, down from 51 in Q4 2023.
- Funds reported $6.91M of Matinas BioPharma stock for Q1 2024, up 23% quarter-over-quarter.
- 3 funds opened new Matinas BioPharma positions in Q1 2024 and 10 closed out, a net change of -7 holders.
- The largest Matinas BioPharma buyer in Q1 2024 was Geode Capital Management, an estimated $133K added.
- The largest Matinas BioPharma seller in Q1 2024 was Connective Capital Management, an estimated $68.7K sold.
Based on aggregated 13F filings for Q1 2024.